Engineered immune cells take aim at deadly lung cancer
NCT ID NCT07509034
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein called B7-H3 found on cancer cells, and infusing them back into the body. The study will enroll 40 participants to evaluate safety and determine the best dose, with follow-up lasting up to 15 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B7-H3 CAR T cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced small cell lung cancer or similar cancers that have stopped responding to standard therapy.
What could go wrong
This is an early phase 1 trial with only 40 participants, so it is primarily testing safety. The treatment may not shrink tumors, and there are risks from chemotherapy and potential side effects from the modified cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••